Novel target genes and a valid biomarker panel identified for cholangiocarcinoma

Epigenetics

Volumn 7, Issue 11, 2012, Pages 1249-1257

  Andresen, Kim ^a,b   Boberg, Kirsten Muri ^a   Vedeld, Hege Marie ^a,b   Hektoen, Merete ^a,b   Wadsworth, Christopher A ^c   Clausen, Ole Petter ^a   Karlsen, Tom Hemming ^a   Foss, Aksel ^a,b   Mathisen, Øystein ^a   Schrumpf, Erik ^a,b   Lothe, Ragnhild A ^a,b   Lind, Guro E ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; CDO1; Cholangiocarcinoma; DCLK1; DNA methylation; Primary sclerosing cholangitis; SFRP1; ZSCAN18

Indexed keywords

EID: 84868368879     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.22191     Document Type: Article

References (51)

1. Khan SA. Thomas HC. Davidson BR. Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005. 366:1303-1314.PMID:16214602. http://dx.doi.org/10.1016/S0140-6736(05)67530-7.
2. Shaib YH. Davila JA. McGlynn K. El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004. 40:472-477. PMID:15123362. http://dx.doi.org/10.1016/j.jhep.2003.11.030.
3. Boberg KM. Bergquist A. sMitchell S. Pares A. Rosina F. Broomé U. et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002. 37:1205-1211. PMID:12408527. http://dx.doi.org/10.1080/003655202760373434.
4. Burak K. Angulo P. Pasha TM. Egan K. Petz J. Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004. 99:523-526. PMID:15056096. http://dx.doi.org/10.1111/j.1572-0241.2004.04067.x.
5. Sripa B. Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol 2008. 24:349-356. PMID:18408464. ttp://dx.doi.org/10.1097/MOG.0b013e3282fbf9b3.
6. Campbell WL. Ferris JV. Holbert BL. Thaete FL. Baron RL. Biliary tract carcinoma complicating primary sclerosing cholangitis: evaluation with CT. cholangiography. US. and MR imaging. Radiology 1998. 207:41-50. PMID:9530297.
7. Bonney GK. Craven RA. Prasad R. Melcher AF. Selby PJ. Banks RE. Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol 2008. 9:149-158. PMID:18237849. http://dx.doi.org/10.1016/S1470-2045(08)70027-5.
8. Nehls O. Gregor M. Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004. 24:139-154. PMID:15192787. http://dx.doi.org/10.1055/s-2004-828891.
9. Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jørgensen J, Wolf H., et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 1999. 45:54-61. PMID:9895338.
10. Akdoǧan M. Saşmaz N. Kayhan B. Biyikoǧlu I. Dişibeyaz S. Sahin B. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori 2001. 87:337-339. PMID:11765186.
11. Steinberg W. The clinical utility of the CA 19-9 tumorassociated antigen. Am J Gastroenterol 1990. 85:350-355. PMID:2183589.
12. Jones PA. Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002. 3:415-428.PMID:12042769.
13. Markowitz SD. Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009. 361:2449-2460. PMID:20018966. http://dx.doi.org/10.1056/NEJMra0804588.
14. Hanahan D. Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011. 144:646-674.PMID:21376230. http://dx.doi.org/10.1016/j.cell.2011.02.013.
15. Hatziapostolou M. Iliopoulos D. Epigenetic aberrations during oncogenesis. Cell Mol Life Sci 2011. 68:1681-1702. PMID:21249513. http://dx.doi.org/10.1007/s00018-010-0624-z.
16. Brooks J. Cairns P. Zeleniuch-Jacquotte A. Promoter methylation and the detection of breast cancer. Cancer Causes Control 2009. 20:1539-1550. PMID:19768562.http://dx.doi.org/10.1007/s10552-009-9415-y.
17. Suzuki H. Tokino T. Shinomura Y. Imai K. Toyota M. DNA methylation and cancer pathways in gastrointestinal tumors. Pharmacogenomics 2008. 9:1917-1928. PMID:19072648. http://dx.doi.org/10.2217/14622416.9.12.1917.
18. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002. 16:6-21. PMID:11782440.http://dx.doi.org/10.1101/gad.947102.
19. Chan AO. Broaddus RR. Houlihan PS. Issa JP. Hamilton SR. Rashid A. CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol 2002. 160:1823-1830. PMID:12000733. http://dx.doi.org/10.1016/S0002-9440(10)61128-5.
20. Baylin SB. Herman JG. Graff JR. Vertino PM. Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998. 72:141-196.PMID:9338076. http://dx.doi.org/10.1016/S0065-230X(08)60702-2.
21. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004. 4:707-717. PMID:15343277. http://dx.doi.org/10.1038/nrc1432.
22. Fujiwara K. Fujimoto N. Tabata M. Nishii K. Matsuo K. Hotta K. et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 2005. 11:1219-1225. PMID:15709192.
23. Park SY. Kwon HJ. Lee HE. Ryu HS. Kim SW. Kim JH. et al. Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch 2011. 458:73-84. PMID:21120523. http://dx.doi.org/10.1007/s00428-010-1013-6.
24. Lind GE. Kleivi K. Meling GI. Teixeira MR. Thiis- Evensen E. Rognum TO. et al. ADAMTS1. CRABP1. and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol 2006. 28:259-272. PMID:17167179.
25. Miller G. Socci ND. Dhall D. D'Angelica M. DeMatteo RP. Allen PJ. et al. Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. J Exp Clin Cancer Res 2009. 28:62. PMID:19435499.http://dx.doi.org/10.1186/1756-9966-28-62.
26. Obama K. Ura K. Li M. Katagiri T. Tsunoda T. Nomura A. et al. Genome-wide analysis of gene expression in humn intrahepatic cholangiocar cinoma. Hepatology 2005. 41:1339-1348. PMID:15880566.http://dx.doi.org/10.1002/hep.20718.
27. Sriraksa R. Zeller C. El-Bahrawy MA. Dai W. Daduang J. Jearanaikoon P. et al. CpG-island methylation study of liver fluke-related cholangiocarcinoma. Br J Cancer 2011. 104:1313-1318. PMID:21448164. http://dx.doi.org/10.1038/bjc.2011.102.
28. Uhm KO. Lee ES. Lee YM. Kim HS. Park YN. Park SH. Aberrant promoter CpG islands methylation of tumor suppressor genes in cholangiocarcinoma. Oncol Res 2008. 17:151-157. PMID:18773859. http://dx.doi.org/10.3727/096504008785114110.
29. Lodygin D. Epanchintsev A. Menssen A. Diebold J. Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005. 65:4218-4227. PMID:15899813. http://dx.doi.org/10.1158/0008-5472.CAN-04-4407.
30. Sato N. Matsubayashi H. Abe T. Fukushima N. Goggins M. Epigenetic down-regulation of CDKN1C/ p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res 2005. 11:4681-4688. PMID:16000561. http://dx.doi.org/10.1158/1078-0432.CCR-04-2471.
31. Costa VL. Henrique R. Danielsen SA. Duarte-Pereira S. Eknaes M. Skotheim RI. et al. Three epigeneticbiomarkers, GDF15, TMEFF2, and VIM. Accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 2010. 16:5842-5851.PMID:20975101. http://dx.doi.org/10.1158/1078-0432.CCR-10-1312.
32. Lind GE, Ahlquist T, Lothe RA, DNA hypermethylation of MAL: a promising diagnostic biomarker for colorectal tumors. Gastroenterology 2007. 132:1631-1632. PMID:17408629. http://dx.doi.org/10.1053/j.gastro.2007.03.003.
33. Lind GE. Danielsen SA. Ahlquist T. Merok MA. Andresen K. Skotheim RI. et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer 2011. 10:85. PMID:21777459. http://dx.doi.org/10.1186/1476-4598-10-85.
34. Shin SH. Lee K. Kim BH. Cho NY. Jang JY. Kim YT. et al. Bile-based detection of extrahepatic cholangiocarcinoma with quantitative DNA methylation markers and its high sensitivity. J Mol Diagn 2012. 14:256-263. PMID:22446083. http://dx.doi.org/10.1016/j.jmoldx.2012.01.014.
35. Gonzalo V, Lozano JJ, Muñoz J, Balaguer F, Pellisé M, Rodríguez de Miguel C., et al. Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer. PLoS One 2010. 5:e8777. PMID:20098741. http://dx.doi.org/10.1371/journal.pone.0008777.
36. Huang ZH. Hu Y Hua D Wu YY Song MX Cheng ZH. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma. Exp Mol Pathol 2011. 91:702-707. PMID:21884695. http://dx.doi.org/10.1016/j.yexmp.2011.08.004.
37. Kawano Y. Kypta R. Secreted antagonists of theWnt signalling pathway. J Cell Sci 2003. 116:2627-2634. PMID:12775774. http://dx.doi.org/10.1242/jcs.00623.
38. Tsuboyama-Kasaoka N. Hosokawa Y. Kodama H. Matsumoto A. Oka J. Totani M. Human cysteine dioxygenase gene: structural organization. Tissuespecific expression and downregulation by phorbol 12-myristate 13-acetate. Biosci Biotechnol Biochem 1999. 63:1017-1024. PMID:10427686. http://dx.doi.org/10.1271/bbb.63.1017.
39. Dietrich D. Krispin M. Dietrich J. Fassbender A. Lewin J. Harbeck N. et al. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated. estrogen receptor-positive. lymph node-positive breast cancer patients. BMC Cancer 2010. 10:247.PMID:20515469. http://dx.doi.org/10.1186/1471-2407-10-247.
40. Kwon YJ. Lee SJ. Koh JS. Kim SH. Lee HW. Kang MC. et al. Genome-Wide Analysis of DNA Methylation and the Gene Expression Change in Lung Cancer. J Thorac Oncol 2011. 7:20-33. PMID:22011669.
41. Mossman D. Scott RJ. Long term transcriptional reactivation of epigenetically silenced genes in colorectal cancer cells requires DNA hypomethylation and histone acetylation. PLoS One 2011. 6:e23127.PMID:21829702. http://dx.doi.org/10.1371/journal.pone.0023127.
42. Maschietto M. Piccoli FS. Costa CM. Camargo LP, Neves JI, Grundy PE. et al. Gene expression analysis of blastemal component reveals genes associated with relapse mechanism in Wilms tumour. Eur J Cancer 2011. 47:2715-2722. PMID:21703850. http://dx.doi.org/10.1016/j.ejca.2011.05.024.
43. Sureban SM. May R. Lightfoot SA. Hoskins AB. Lerner M. Brackett DJ. et al. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res 2011. 71:2328-2338. PMID:21285251.http://dx.doi.org/10.1158/0008-5472.CAN-10-2738.
44. Souza RF. Krishnan K. Spechler SJ. Acid, bile, And CDX: the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol 2008. 295:G211-G218. PMID:18556417. http://dx.doi.org/10.1152/ajpgi.90250.2008.
45. Morris MR. Ricketts CJ. Gentle D. McRonald F. Carli N, Khalili H., et al. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene 2011. 30:1390-1401. PMID:21132003. http://dx.doi.org/10.1038/onc.2010.525.
46. Moreno Luna LE. Gores GJ. Advances in the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver Transpl 2006. 12(Suppl 2):S15-S19.PMID:17051561. http://dx.doi.org/10.1002/lt.20938.
47. Oster B, Thorsen K, Lamy P, Wojdacz TK, Hansen LL, Birkenkamp-Demtröder K. et al. Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer 2011. 129:2855-2866. PMID:21400501. http://dx.doi.org/10.1002/ijc.25951.
48. Geng J, Sun J, Lin Q, Gu J, Zhao Y, Zhang H, et al. Methylation status of NEUROG2 and NID2 improves the diagnosis of stage I NSCLC. Oncol Lett 2012.3:901-906. PMID:22741015.
49. Sharma G. Mirza S. Prasad CP. Srivastava A. Gupta SD. Ralhan R. Promoter hypermethylation of p16INK4A. p14ARF. CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci 2007. 80:1873-1881. PMID:17383681. http://dx.doi.org/10.1016/j.lfs.2007.02.026.
50. Weisenberger DJ. Campan M. Long TI. Kim M. Woods C. Fiala E. et al. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 2005. 33:6823-68736. PMID:16326863. http://dx.doi.org/10.1093/nar/gki987.
51. Rawson JB. Manno M. Mrkonjic M. Daftary D. Dicks E. Buchanan DD. et al. Promoter methylationof Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large poplations of colorectal cancer patients. Carcinogenesis 2011. 32:741-747. PMID:21304055. http://dx.doi.org/10.1093/carcin/bgr020.